{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-006581","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2022-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.050983+00:00","generated_at":"2026-06-26T03:32:07.894487+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Finch Therapeutics announces FDA removal of clinical hold on CP101 IND; prepares to resume PRISM4 Phase 3 trial","bullets":["FDA lifted clinical hold on CP101 IND after Finch provided SARS-CoV-2 screening data and revised consent language.","CP101 is an oral microbiome therapeutic for recurrent C. difficile infection, in late-stage development.","PRISM4 enrollment to resume after manufacturing activities, quality updates, and FDA agreement on protocol amendment and validation package.","Timing update for PRISM4 and AUSPIRE Phase 1b trial of FIN-211 expected with Q1 2022 results."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-006581","json":"https://secwatch.observer/filing/0000950170-22-006581.json","markdown":"https://secwatch.observer/filing/0000950170-22-006581.md","text":"https://secwatch.observer/filing/0000950170-22-006581.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022006581/0000950170-22-006581-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022006581/fnch-20220428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T03:32:07.894487+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}